Juno Therapeutics, Inc. (JUNO): Hans Edgar Bishop , CEO & President of Juno Therapeutics, Inc. sold 84,035 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $30.10 per share for a total value of $2,544,431.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 9, 2016, Hans Edgar Bishop (CEO & President) sold 23,042 shares at $30.06 per share price.On Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at $40.71 per share price.Also, On Jun 21, 2016, Hyam Levitsky (EVP, Research & CSO) sold 12,418 shares at $42.98 per share price.On Jun 13, 2016, Steve Harr (CFO & Head, Corp. Development) sold 30,000 shares at $43.29 per share price.
Juno Therapeutics Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Juno Therapeutics Inc which led to swings in the share price. The shares opened for trading at $29.52 and hit $30.03 on the upside , eventually ending the session at $29.75, with a gain of 1.92% or 0.56 points. The heightened volatility saw the trading volume jump to 11,38,848 shares. The 52-week high of the share price is $57.82 and the company has a market cap of $3,147 M . The 52-week low of the share price is at $22.37.
Company has been under the radar of several Street Analysts.Juno Therapeutics Inc is Reiterated by Maxim Group to Buy while Lowering the Price Target of the company shares to $ 50 from a previous price target of $80 . The Rating was issued on Aug 5, 2016.Juno Therapeutics Inc is Reiterated by FBR Capital to Outperform while Lowering the Price Target of the company shares to $ 61 from a previous price target of $73 . The Rating was issued on Jul 8, 2016.Juno Therapeutics Inc is Downgraded by JP Morgan to Neutral while Lowering the Price Target of the company shares to $ 39 from a previous price target of $63 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jul 8, 2016.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.